Alnylam Pharmaceuticals, Inc. (ALNY) stock
ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$156.50−3.23 (-2.02%)
Close on Nov 17, 2026Market cap $20.96BP/E 8.1Yield –
Alnylam Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
Alnylam Pharmaceuticals's operating margin for the twelve months ending Sep 30, 2026 was 19.5%. For fiscal 2025 it was 13.5%, against -7.9% the year before. The highest annual figure on record is 13.5% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 13.5% | +21.4 |
| FY2024 | Dec 31, 2024 | -7.9% | +7.6 |
| FY2023 | Dec 31, 2023 | -15.4% | +60.2 |
| FY2022 | Dec 31, 2022 | -75.7% | +8.3 |
| FY2021 | Dec 31, 2021 | -83.9% | +84.2 |
| FY2020 | Dec 31, 2020 | -168.1% | +259.4 |
| FY2019 | Dec 31, 2019 | -427.5% | +660.1 |
| FY2018 | Dec 31, 2018 | -1087.6% | −531.4 |
| FY2017 | Dec 31, 2017 | -556.2% | +344.1 |
| FY2016 | Dec 31, 2016 | -900.3% | −856.3 |
| FY2010 | Dec 31, 2010 | -44.1% | +3.8 |
| FY2009 | Dec 31, 2009 | -47.9% | −18.9 |
| FY2008 | Dec 31, 2008 | -28.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 23.7% | −5.7 |
| Q2 FY2026 | Jun 30, 2026 | 17.9% | +20.0 |
| Q1 FY2026 | Mar 31, 2026 | 23.0% | +20.0 |
| Q4 FY2025 | Dec 31, 2025 | 12.0% | +29.7 |
| Q3 FY2025 | Sep 30, 2025 | 29.5% | +44.8 |
| Q2 FY2025 | Jun 30, 2025 | -2.1% | −9.5 |
| Q1 FY2025 | Mar 31, 2025 | 3.0% | +11.8 |
| Q4 FY2024 | Dec 31, 2024 | -17.7% | +8.7 |
| Q3 FY2024 | Sep 30, 2024 | -15.4% | −43.8 |
| Q2 FY2024 | Jun 30, 2024 | 7.4% | +79.5 |
| Q1 FY2024 | Mar 31, 2024 | -8.8% | +38.1 |
| Q4 FY2023 | Dec 31, 2023 | -26.5% | +29.8 |
| Q3 FY2023 | Sep 30, 2023 | 28.5% | +126.1 |
| Q2 FY2023 | Jun 30, 2023 | -72.1% | +13.2 |
| Q1 FY2023 | Mar 31, 2023 | -46.9% | +21.9 |
| Q4 FY2022 | Dec 31, 2022 | -56.3% | +19.0 |
| Q3 FY2022 | Sep 30, 2022 | -97.6% | −0.8 |
| Q2 FY2022 | Jun 30, 2022 | -85.3% | −19.0 |
| Q1 FY2022 | Mar 31, 2022 | -68.8% | +36.1 |
| Q4 FY2021 | Dec 31, 2021 | -75.3% | +43.5 |
| Q3 FY2021 | Sep 30, 2021 | -96.8% | +82.1 |
| Q2 FY2021 | Jun 30, 2021 | -66.3% | +125.0 |
| Q1 FY2021 | Mar 31, 2021 | -104.9% | +106.4 |
| Q4 FY2020 | Dec 31, 2020 | -118.7% | +297.1 |
| Q3 FY2020 | Sep 30, 2020 | -178.9% | +129.8 |
| Q2 FY2020 | Jun 30, 2020 | -191.3% | +337.1 |
| Q1 FY2020 | Mar 31, 2020 | -211.3% | +355.8 |
| Q4 FY2019 | Dec 31, 2019 | -415.8% | +631.8 |
| Q3 FY2019 | Sep 30, 2019 | -308.7% | +11994.7 |
| Q2 FY2019 | Jun 30, 2019 | -528.4% | +114.8 |
| Q1 FY2019 | Mar 31, 2019 | -567.0% | +106.1 |
| Q4 FY2018 | Dec 31, 2018 | -1047.7% | −659.3 |
| Q3 FY2018 | Sep 30, 2018 | -12303.4% | −11567.6 |
| Q2 FY2018 | Jun 30, 2018 | -643.2% | +113.0 |
| Q1 FY2018 | Mar 31, 2018 | -673.1% | −111.3 |
| Q4 FY2017 | Dec 31, 2017 | -388.4% | – |
| Q3 FY2017 | Sep 30, 2017 | -735.8% | – |
| Q2 FY2017 | Jun 30, 2017 | -756.2% | – |
| Q1 FY2017 | Mar 31, 2017 | -561.8% | – |
See a number that looks wrong?